Cargando…

Clinical use of HD-MTX monotherapy in a rare case of refractory primary bone diffuse large B-cell lymphoma with long-term survival after local radiotherapy: A case report

Primary bone diffuse large B-cell lymphoma (PB-DLBCL) has been rarely reported because of its low incidence. The optimal treatment plan for patients with relapsed/refractory PB-DLBCL remains controversial. In this study, we present a case of a 57-year-old patient with refractory PB-DLBCL to better u...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Zhiya, Teng, Yue, Wu, Jianqiu, Zhang, Honglu, Peng, Weiwei, Meng, Cheng, Tang, Weiyan, Feng, Jifeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9810803/
https://www.ncbi.nlm.nih.gov/pubmed/36619626
http://dx.doi.org/10.3389/fmed.2022.989590
_version_ 1784863384297013248
author Wu, Zhiya
Teng, Yue
Wu, Jianqiu
Zhang, Honglu
Peng, Weiwei
Meng, Cheng
Tang, Weiyan
Feng, Jifeng
author_facet Wu, Zhiya
Teng, Yue
Wu, Jianqiu
Zhang, Honglu
Peng, Weiwei
Meng, Cheng
Tang, Weiyan
Feng, Jifeng
author_sort Wu, Zhiya
collection PubMed
description Primary bone diffuse large B-cell lymphoma (PB-DLBCL) has been rarely reported because of its low incidence. The optimal treatment plan for patients with relapsed/refractory PB-DLBCL remains controversial. In this study, we present a case of a 57-year-old patient with refractory PB-DLBCL to better understand this disease. The patient developed lumbosacral/low extremity pain. A lumbar magnetic resonance imaging (MRI) revealed skeletal lesions with osteolysis in L4-L5 and S1. With the failure of multi-line chemotherapy, the patient developed paralysis of both lower limbs. 18-Fluorinefluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) and MRI showed new lesions in the femoral head, cervical and thoracic vertebrae. We tried to treat the patient with adjuvant radiotherapy and 10 courses of high-dose methotrexate (HD-MTX)-based monotherapy, after which the patient was able to walk and achieved complete remission (CR). To the best of our knowledge, this is the first attempt to use local radiotherapy combined with an HD-MTX regimen successfully for the treatment of refractory PB-DLBCL.
format Online
Article
Text
id pubmed-9810803
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-98108032023-01-05 Clinical use of HD-MTX monotherapy in a rare case of refractory primary bone diffuse large B-cell lymphoma with long-term survival after local radiotherapy: A case report Wu, Zhiya Teng, Yue Wu, Jianqiu Zhang, Honglu Peng, Weiwei Meng, Cheng Tang, Weiyan Feng, Jifeng Front Med (Lausanne) Medicine Primary bone diffuse large B-cell lymphoma (PB-DLBCL) has been rarely reported because of its low incidence. The optimal treatment plan for patients with relapsed/refractory PB-DLBCL remains controversial. In this study, we present a case of a 57-year-old patient with refractory PB-DLBCL to better understand this disease. The patient developed lumbosacral/low extremity pain. A lumbar magnetic resonance imaging (MRI) revealed skeletal lesions with osteolysis in L4-L5 and S1. With the failure of multi-line chemotherapy, the patient developed paralysis of both lower limbs. 18-Fluorinefluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) and MRI showed new lesions in the femoral head, cervical and thoracic vertebrae. We tried to treat the patient with adjuvant radiotherapy and 10 courses of high-dose methotrexate (HD-MTX)-based monotherapy, after which the patient was able to walk and achieved complete remission (CR). To the best of our knowledge, this is the first attempt to use local radiotherapy combined with an HD-MTX regimen successfully for the treatment of refractory PB-DLBCL. Frontiers Media S.A. 2022-12-21 /pmc/articles/PMC9810803/ /pubmed/36619626 http://dx.doi.org/10.3389/fmed.2022.989590 Text en Copyright © 2022 Wu, Teng, Wu, Zhang, Peng, Meng, Tang and Feng. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Wu, Zhiya
Teng, Yue
Wu, Jianqiu
Zhang, Honglu
Peng, Weiwei
Meng, Cheng
Tang, Weiyan
Feng, Jifeng
Clinical use of HD-MTX monotherapy in a rare case of refractory primary bone diffuse large B-cell lymphoma with long-term survival after local radiotherapy: A case report
title Clinical use of HD-MTX monotherapy in a rare case of refractory primary bone diffuse large B-cell lymphoma with long-term survival after local radiotherapy: A case report
title_full Clinical use of HD-MTX monotherapy in a rare case of refractory primary bone diffuse large B-cell lymphoma with long-term survival after local radiotherapy: A case report
title_fullStr Clinical use of HD-MTX monotherapy in a rare case of refractory primary bone diffuse large B-cell lymphoma with long-term survival after local radiotherapy: A case report
title_full_unstemmed Clinical use of HD-MTX monotherapy in a rare case of refractory primary bone diffuse large B-cell lymphoma with long-term survival after local radiotherapy: A case report
title_short Clinical use of HD-MTX monotherapy in a rare case of refractory primary bone diffuse large B-cell lymphoma with long-term survival after local radiotherapy: A case report
title_sort clinical use of hd-mtx monotherapy in a rare case of refractory primary bone diffuse large b-cell lymphoma with long-term survival after local radiotherapy: a case report
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9810803/
https://www.ncbi.nlm.nih.gov/pubmed/36619626
http://dx.doi.org/10.3389/fmed.2022.989590
work_keys_str_mv AT wuzhiya clinicaluseofhdmtxmonotherapyinararecaseofrefractoryprimarybonediffuselargebcelllymphomawithlongtermsurvivalafterlocalradiotherapyacasereport
AT tengyue clinicaluseofhdmtxmonotherapyinararecaseofrefractoryprimarybonediffuselargebcelllymphomawithlongtermsurvivalafterlocalradiotherapyacasereport
AT wujianqiu clinicaluseofhdmtxmonotherapyinararecaseofrefractoryprimarybonediffuselargebcelllymphomawithlongtermsurvivalafterlocalradiotherapyacasereport
AT zhanghonglu clinicaluseofhdmtxmonotherapyinararecaseofrefractoryprimarybonediffuselargebcelllymphomawithlongtermsurvivalafterlocalradiotherapyacasereport
AT pengweiwei clinicaluseofhdmtxmonotherapyinararecaseofrefractoryprimarybonediffuselargebcelllymphomawithlongtermsurvivalafterlocalradiotherapyacasereport
AT mengcheng clinicaluseofhdmtxmonotherapyinararecaseofrefractoryprimarybonediffuselargebcelllymphomawithlongtermsurvivalafterlocalradiotherapyacasereport
AT tangweiyan clinicaluseofhdmtxmonotherapyinararecaseofrefractoryprimarybonediffuselargebcelllymphomawithlongtermsurvivalafterlocalradiotherapyacasereport
AT fengjifeng clinicaluseofhdmtxmonotherapyinararecaseofrefractoryprimarybonediffuselargebcelllymphomawithlongtermsurvivalafterlocalradiotherapyacasereport